For research use only. Not for therapeutic Use.
Bifonazole（Cat No.:I004285） is an imidazole antifungal drug used for the treatment of various fungal infections. It belongs to the azole class of antifungal agents and works by inhibiting the synthesis of ergosterol, an essential component of the fungal cell membrane. By disrupting the integrity of the cell membrane, bifonazole effectively prevents the growth and proliferation of fungi, thereby treating conditions such as athlete’s foot, ringworm, and yeast infections. Bifonazole is available in topical formulations, including creams, powders, and sprays, making it convenient for localized fungal infections on the skin or nails.
| Catalog Number | I004285 |
| CAS Number | 60628-96-8 |
| Synonyms | BAY-h 4502;(±)-Bifonazole |
| Molecular Formula | C22H18N2 |
| Purity | ≥95% |
| Target | Antifungal |
| Solubility | DMSO 60 mg/mL; Water <1 mg/mL |
| Storage | Room Temperature |
| IUPAC Name | 1-[phenyl-(4-phenylphenyl)methyl]imidazole |
| InChI | InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H |
| InChIKey | OCAPBUJLXMYKEJ-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4 |
| Reference | </br>1:Determination of bifonazole and identification of its photocatalytic degradation products using UPLC-MS/MS. Kryczyk A, Żmudzki P, Hubicka U.Biomed Chromatogr. 2017 Feb 10. doi: 10.1002/bmc.3955. [Epub ahead of print] PMID: 28186351 </br>2:Evaluation of efficacy and tolerability of four weeks bifonazole treatment after nail ablation with 40% urea in mild to moderate distal subungual onychomycosis. Piraccini BM, Bruni F, Alessandrini A, Starace M.G Ital Dermatol Venereol. 2016 Feb;151(1):32-6. Epub 2015 Oct 16. PMID: 26472342 </br>3:Crystallization of bifonazole and acetaminophen within the matrix of semicrystalline, PEO-PPO-PEO triblock copolymers. Chen Z, Liu Z, Qian F.Mol Pharm. 2015 Feb 2;12(2):590-9. doi: 10.1021/mp500661v. Epub 2015 Jan 21. PMID: 25569586 </br>4:The mechanism of bifonazole-induced [Ca(2+)]i rises and non-Ca(2+)-triggered cell death in PC3 human prostate cancer cells. Cheng JS, Chou CT, Liang WZ, Kuo CC, Shieh P, Kuo DH, Jan CR.J Recept Signal Transduct Res. 2014 Dec;34(6):493-9. doi: 10.3109/10799893.2014.921201. Epub 2014 May 22. PMID: 24849495 </br>5:Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: a double-blind, randomized, placebo-controlled multicenter study. Tietz HJ, Hay R, Querner S, Delcker A, Kurka P, Merk HF.Mycoses. 2013 Jul;56(4):414-21. doi: 10.1111/myc.12037. Epub 2013 Apr 16. PMID: 23586591 </br>6:Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study. Lahfa M, Bulai-Livideanu C, Baran R, Ortonne JP, Richert B, Tosti A, Piraccini BM, Szepietowski JC, Sibaud V, Coubetergues H, Voisard JJ, Paul C.Dermatology. 2013;226(1):5-12. doi: 10.1159/000345105. Epub 2013 Mar 1. PMID: 23467055 </br>7:Comparison of superficial mycosis treatment using Butenafine and Bifonazole nitrate clinical efficacy. Abdul Bari MA.Glob J Health Sci. 2012 Nov 11;5(1):150-4. doi: 10.5539/gjhs.v5n1p150. PMID: 23283047 Free PMC Article</br>8:Formulation of thermoresponsive and buccal adhesive in situ gel for treatment of oral thrush containing poorly water soluble drug bifonazole. Patel D, Patel D, Prajapati J, Patel U, Patel V.J Pharm Bioallied Sci. 2012 Mar;4(Suppl 1):S116-7. doi: 10.4103/0975-7406.94163. PMID: 23066185 Free PMC Article</br>9:Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole. Wächtler B, Wilson D, Hube B.Antimicrob Agents Chemother. 2011 Sep;55(9):4436-9. doi: 10.1128/AAC.00144-11. Epub 2011 Jul 11. PMID: 21746947 Free PMC Article</br>10:Synthesis, antibacterial and antifungal activities of bifonazole derivatives. El Hage S, Lajoie B, Feuillolay C, Roques C, Baziard G.Arch Pharm (Weinheim). 2011 Jun;344(6):402-10. doi: 10.1002/ardp.201000304. Epub 2011 Mar 24. PMID: 21433056 |
